Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 17/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113076 | 0.85 | GRIA2 (0.51) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL3098453 | 0.84 | GRIA2 (0.54) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL14291977 | 0.84 | KDM4E (0.38) | GRIA2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3114522 | 0.83 | GRIA2 (0.53) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL3100660 | 0.80 | CYP1A2 (0.59) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL4032258 | 0.79 | GRIA2 (0.55) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL3107408 | 0.79 | GRIA2 (0.77) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL3113696 | 0.78 | GRIA2 (0.51) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL3102879 | 0.77 | GRIA2 (0.48) | GRIA2CYP1A2CYP2D6CYP2C9GAA | |
| SCHEMBL14292377 | 0.76 | GRIA2 (0.51) | GRIA2CYP1A2CYP2D6CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | GRIA2 4028/4885CYP1A2 1112/4885CYP2D6 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.